Prolactin and cortisol responses to fenfluramine in Parkinson's disease

Biological Psychiatry

Volumn 40, Issue 8, 1996, Pages 769-775

  Kostić, Vladimir S ^a,b   Lečić, Dusica ^a   Doder, Miroslava ^a   Marinković, Jelena ^a   Filipović, Saša ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b Institute of Neurology   (Yugoslavia)

Author keywords

cortisol; depression; fenfluramine; Parkinson's disease; prolactin; serotonin

Indexed keywords

FENFLURAMINE; HYDROCORTISONE; PROLACTIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; DROWSINESS; FEMALE; HUMAN; MALE; NAUSEA; ORAL DRUG ADMINISTRATION; PARKINSON DISEASE; PRIORITY JOURNAL; PROVOCATION TEST; VOMITING;

EID: 0030588102     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/0006-3223(95)00496-3     Document Type: Article

References (43)

1. Agid Y, Cervera P, Hirsch E, Javoy-Agid F, Lehericy S, Raisman R, Ruberg M (1989): Biochemistry of Parkinson's disease 28 years later: A critical review. Movement Disord 4(suppl 1):S1126-S1144.
2. Asnis GM, Eisenberg J, van Praag HM, Lemus CZ, Friedman JMH, Miller AH (1988): The neuroendocrine response to fenfluramine in depressives and normal controls. Biol Psychiatry 24:117-120.
3. Canter GJ, de La Torre R, Mier M (1961): A method for evaluating disability in patients with Parkinson's disease. J Nerv Ment Dis 133:143-147.
4. Coccaro EF, Siever LJ, Klar HM, Maurer G, Cochrane K, Cooper TB, Mohs RC, Davis KL (1989): Serotonergic studies in patients with affective and personality disorders. Arch Gen Psychiatry 46:587-599.
5. Costa EA, Groppetti A, Revuelta A (1971): Action of fenfluramine on monoamine stores of rat tissue. Br J Pharmacol 41:57-64.
6. Eisler T, Thorner MD, MacLeod RM, Kaiser DL, Calne DB (1981): Prolactin secretion in Parkinson disease. Neurology 31:1356-1359.
7. Endicott J, Spitzer RL (1978): A diagnostic interview: The Schedule for Affective Disorders and Schizophrenia. Arch Gen Psychiatry 35:837-844.
8. Foresta C, Scanelli G, Indino M, Federspil G, Scandellari C (1985): Naloxone reduces the fenfluramine-induced prolactin release in man. Clin Endocrinol 22:539-543.
9. Fuller RW (1990): Serotonin receptors and neuroendocrine responses. Neuropsychopharmacology 3:495-502.
10. Garattini S, Caccia S, Mennini T, Samanin R, Consolo S, Ladinsky H (1979): Biochemical pharmacology of the anorectic drug fenfluramine: A review. Curr Med Res Opin 6(suppl 1):15-27.
11. Gotham AM, Brown RG, Marsden CD (1986): Depression in Parkinson's disease: A quantitative and qualitative analysis. J Neurol Neurosurg Psychiatry 49:381-389.
12. Hamilton M (1960): A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56-62.
13. Hoehn MM, Yahr MD (1967): Parkinsonism: Onset, progression and mortality. Neurology 17:427-442.
14. Kostić VS, Djuričić BM, Čovičković-Šternić N, Bumbaširević Lj, Nikolić M, Mršulja BB (1987): Depression and Parkinson's disease: Possible role of serotonergic mechanisms. J Neurol 234:94-96.
15. Kostić VS, Marinković Z, Momčilović D, Šternić N (1993): Function of dopamine receptors in young-onset Parkinson's disease. Movement Disord 8:227-229.
16. Laihinen A, Rinne UK (1986): Function of dopamine receptors in Parkinson's disease: Prolactin response. Neurology 36: 393-395.
17. Lewis DA, Sherman BM (1984): Serotonergic stimulation of adrenocorticotropin secretion in man. J Clin Endocrinol Metab 58:458-462.
18. Lewis DA, Sherman BM (1985): Serotonergic regulation of prolactin and growth hormone secretion in man. Acta Endocrinol 110:152-157.
19. Lopez-Ibor JJ, Saiz-Reuz J, Iglesias LM (1988): The fenfluramine challenge test in the affective spectrum: A possible marker of endogenecity and severity. Pharmacopsychiatria 21:9-14.
20. Maes M, De Ruyter M, Claes R, Bosma G, Suy E (1987): The cortisol responses to 5-hydroxytryptophan, orally, in depressive inpatients. J Affective Disord 13:23-30.
21. Maes M, Jacobs MP, Suy E, Minner B, Raus J (1989): Cortisol, ACTH, prolactin and beta-endorphin responses to fenfluramine administration in major-depressed patients. Pharmacopsychiatry 21:192-196.
22. Martin JB, Reichlin S (1987): Clinical Neuroendocrinology. Philadelphia: Davis.
23. Mayeux R, Stern Y, Cote L, Williams JB (1984): Altered serotonin metabolism in depressed patients with Parkinson's disease. Neurology 34:642-646.
24. Mayeux R (1990): Depression in the patient with Parkinson's disease. J Clin Psychiatry 51:20-25.
25. Meltzer HY, Wiita B, Robertson A, Tricou BJ, Lowy M, Perline R (1984): Effect of 5-hydroxytryptophan on serum cortisol levels in major affective disorders: Enhanced response in depression and mania. Arch Gen Psychiatry 41:366-374.
26. Mitchell P, Smythe G (1990): Hormonal responses to fenfluramine in depressed and control subjects. J Affective Disord 19:43-51.
27. Murphy DL, Mueller EA, Garrick NA, Aulakh CS (1986): Use of serotonergic agents in the clinical assessment of central serotonin function. J Clin Psychiatry 47:9-15.
28. O'Keane V, Dinan TG (1991): Prolactin and cortisol responses to d-fenfluramine in major depression: Evidence for diminished responsivity of central serotonergic function. Am J Psychiatry 148:1009-1015.
29. Preziosi P (1983): Serotonin control of prolactin release: An intriguing puzzle. Trends Pharmacol Sci 4:171-174.
30. Quattrone A, Tedeschi G, Aguglia U, Scopacasa F, Di Renzo GF, Annunziato L (1983): Prolactin secretion in man: A useful tool to evaluate the activity of drugs on central 5-hydroxytryptaminergic neurones. Studies with fenfluramine. Br J Clin Pharmacol 16:471-475.
31. Raleigh MJ, Brammer GL, Ritvo ER, Geller E, McGuire MT, Yuwiler A (1986): Effects of chronic fenfluramine on blood serotonin, cerebrospinal fluid metabolites, and behavior in monkeys. Psychopharmacology 990:503-508.
32. Rowland NE, Carlton J (1986): Neurobiology of an anorectic drug: Fenfluramine. Prog Neurobiol 27:13-62.
33. Sano M, Stanley M, Lawton A, Cote L, Williams J, Stern Y, Marder K, Mayeux R (1991): Tritiated imipramine binding: A peripheral marker for serotonin in Parkinson's disease. Arch Neurol 48:1052-1054.
34. Shapira B, Reiss A, Kaiser N, Kindler B (1989): Effect of imipramine treatment on the prolactin response to fenfluramine and placebo challenge in depressed patients. J Affective Disord 16:1-4.
35. Shapira B, Cohen J, Newman ME, Lerer B (1993): Prolactin response to fenfluramine and placebo challenge following maintenance pharmacotherapy withdrawal in remitted depressed patients. Biol Psychiatry 33:531-535.
36. Siever LJ, Murphy DL, Slater S, de la Verga E, Lipper S (1984): Plasma prolactin changes following fenfluramine in depressed patients compared to controls: An evaluation of central serotonergic responsivity in depression. Life Sci 34: 1029-1039.
37. Spitzer RL, Endicott J, Robins E (1978): Research Diagnostic Criteria: Rationale and reliability. Arch Gen Psychiatry 35: 773-782.
38. Taylor AE, Saint-Cyr JA (1990): Depression in Parkinson's disease: Reconciling physiological and psychological perspectives. J Neuropsychiatry 2:92-98.
39. Van de Kar LD, Urban JH, Richardson KD, Bethea CL (1985): Pharmacological studies on the serotonergic and nonserotonin-mediated stimulation of prolactin and corticosterone secretion by fenfluramine. Neuroendocrinology 41:283-288.
40. van Praag HM, Korf J, Puite J (1970): 5-Hydroxyindoleacetic acid levels in the cerebrospinal fluid of depressive patients treated with probenecid. Nature 225:1259-1260.
41. van Praag HM, De Haan S (1980): Depression vulnerability and 5-hydroxytryptophan prophylaxis. Psychiatry Res 3:75-83.
42. van Praag HM, Lemus C, Kahn R (1986): The pitfalls of 5-HT precursors as challengers in hormonal probes of central serotonin activity. Psychopharmacology 22:1-12.
43. Weizman A, Mark M, Gil-Ad I, Tyano S, Laron Z (1988): Plasma cortisol, prolactin, growth hormone, and immunoreactive β-endorphin response to fenfluramine challenge in depressed patients. Clin Neuropharmacol 11:250-256.